Evidence map›Paper›PMID 12569072›Full record

ArticleBritish journal of pharmacology2003

Heterogeneity of presynaptic muscarinic receptors mediating inhibition of sympathetic transmitter release: a study with M2- and M4-receptor-deficient mice.

Anne-Ulrike Trendelenburg, Jesus Gomeza, Werner Klebroff, Hongxia Zhou, Jürgen Wess

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. The Role of Muscarinic Acetylcholine Receptor MInternational journal of molecular sciences · 2024
    Review
  3. Review
  4. Article
  5. Cholinergic activity as a new target in diseases of the heart.Molecular medicine (Cambridge, Mass.) · 2015
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Cholinergic innervation of the guinea-pig isolated vas deferens.Naunyn-Schmiedeberg's archives of pharmacology · 2007
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Anne-Ulrike TrendelenburgInstitut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albertstrasse 25, D-79104 Freiburg, Germany. anne-ulrike.trendelenburg@pharma.novartis.com
Jesus Gomeza
Werner Klebroff
Hongxia Zhou
Jürgen Wess
University of Freiburg · DENovartis (Switzerland) · CH

Funding

STUDIES ON NEUROTRANSMITTER RECEPTOR GENESZ01DK032003 · NIDDK · DIABETES, DIGESTIVE, KIDNEY DISEASES · PI WESS, JURGEN · 1993 to 2006
–
6 · The paper itself

Abstract

1 Presynaptic muscarinic receptors modulate sympathetic transmitter release. The goal of the present study was to identify the muscarinic receptor subtype(s) mediating inhibition of sympathetic transmitter release in mouse atria, urinary bladder and vas deferens. To address this question, electrically evoked noradrenaline release was assessed using tissue preparations from NMRI, M(2)- and M(4)-knockout, and the corresponding M(2)- and M(4)-wildtype mice, after preincubation with (3)H-noradrenaline. 2 The muscarinic agonist carbachol decreased evoked tritium overflow (20 pulses/50 Hz) in each tissue and strain investigated. After deletion of the M(2)-receptor the maximal inhibition by carbachol was significantly reduced (by 41-72%), but not abolished, in all tissues. After deletion of the M(4)-receptor a moderate and significant reduction of the maximal inhibition by carbachol (by 28%) was observed only in the vas deferens. 3 Experiments with the muscarinic antagonists methoctramine and pirenzepine confirmed that the presynaptic muscarinic receptors were predominantly M(2) in atria and bladder and probably a mixture of M(2) and M(4) in the vas deferens. 4 Experiments in the urinary bladder with the cholinesterase inhibitor physostigmine and the muscarinic antagonist ipratropium demonstrated that endogenously released acetylcholine predominantly acted through M(2)-receptors to inhibit noradrenaline release. However, the results do not exclude a minor contribution of M(4)-receptors to this endogenous inhibition. 5 In conclusion, our results clearly indicate that the release-inhibiting muscarinic receptors on postganglionic sympathetic axons in mouse atria, bladder and vas deferens represent mixtures of M(2)- and non-M(2)-receptors. The non-M(2)-receptors remain unknown in atria and the bladder, and may represent primarily M(4)-receptors in the vas deferens. These results reveal an unexpected heterogeneity among the muscarinic receptors mediating inhibition of noradrenaline release.

Indexed as

Genetic HeterogeneityAcetylcholineAnimalsCarbacholCholinergic AgonistsDiaminesHeart AtriaMaleMiceMice, KnockoutMuscarinic AntagonistsNorepinephrinePirenzepineReceptor, Muscarinic M2Receptor, Muscarinic M4Receptors, MuscarinicAcetylcholineCarbacholCholinergic AgonistsDiaminesmethoctramineMuscarinic AntagonistsNorepinephrinePirenzepineReceptor, Muscarinic M2Receptor, Muscarinic M4Receptors, MuscarinicReceptors, Presynaptic

Identifiers

PMID12569072
PMCPMC1573680
OpenAlexW2071994886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.